- Effect of L-carnitine against acute mitoxantrone toxicity in mice2008 | First Faculty of Medicine
- Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour2011 | Faculty of Medicine in Hradec Králové
- Effect of L-carnitine against acute mitoxantrone toxicity in mice +12008 | Faculty of Medicine in Hradec Králové
- Evaluation of the antineoplastic activity of mitoxantrone-L-carnitine combination therapy on an experimental solid form of Ehrlich tumour in mice2006 | First Faculty of Medicine
- Evaluation of the antineoplastic activity of mitoxantrone-L-carnitine combination therapy on an experimental solid form of Ehrlich tumour in mice +12006 | Faculty of Medicine in Hradec Králové
- Mitoxanthrone in the treatment of active Multiple sclerosis (MS)2003 | First Faculty of Medicine
- Mitoxanthrone in the treatment of active Multiple sclerosis (MS)2003 | Faculty of Physical Education and Sport
- The effect of ATM and ERK1/2 inhibition on mitoxantrone-induced cell death of leukaemic cells2011 | Faculty of Medicine in Hradec Králové
- Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer2019 | First Faculty of Medicine
- Subcellular Localization of Proteins Responding to Mitoxantrone-Induced DNA Damage in Leukaemic Cells2015 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Mitoxantrone in Combination with a DNA-PK Inhibitor: Possible Therapy of Promyelocytic Leukaemia Resistant Forms2011 | Faculty of Medicine in Hradec Králové
- Mitoxantrone ability to induce premature senescence in human dental pulp stem cells and human dermal fibroblasts2013 | Faculty of Medicine in Hradec Králové
- Current options in the treatment of multiple sclerosis2010 | Second Faculty of Medicine
- Anthracycline antibiotics derivate mitoxantrone-Destructive sorption and photocatalytic degradation2018 | First Faculty of Medicine
- Mitoxantron and inhibition of [8-3H]adenosine incorporation1996 | First Faculty of Medicine
- Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone2012 | Faculty of Pharmacy in Hradec Králové
- Biochemical aspects of possible therapeutic synergism of mitoxantrone with some L-carnitine derivatives, deoxysaccharides and trypsinPublication without faculty affiliation
- Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial2022 | Faculty of Medicine in Hradec Králové
- Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)2011 | Second Faculty of Medicine
- Cabazitaxel in the treatment of a patient with prostate cancer2020 | Publication without faculty affiliation
- Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis2010 | Third Faculty of Medicine
- Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients2005 | First Faculty of Medicine
- Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients2005 | Faculty of Physical Education and Sport
- Cabazitaxel in the treatment of patients with metastatic castration-resistant prostate cancer2014 | First Faculty of Medicine
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial2015 | Second Faculty of Medicine
- Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis2022 | First Faculty of Medicine
- Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax2022 | First Faculty of Medicine
- Multiple sclerosis2011 | First Faculty of Medicine